Newamsterdam Pharma Company N V (NAMSW)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Newamsterdam Pharma Company N V

Healthcare (1161)

Biotechnology (676)

31 35 206 2971

Gooimeer 2-35, Naarden

Prossima data di guadagno

Ultimi documenti SEC

NAMSW's Discussions on Twitter

Confronta NAMSW con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NAMSW Newamsterdam Pharma Company N V	7.32	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Newamsterdam Pharma Company N V Borsa (NAMSW) Ultime notizie

Newamsterdam Pharma Company N V Azioni (NAMSW) Dati Finanziari

Non sono disponibili dati finanziari per Newamsterdam Pharma Company N V (NAMSW). Controlla altri titoli per ulteriori informazioni.

Newamsterdam Pharma Company N V (NAMSW)

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Confronta NAMSW con altri titoli

Newamsterdam Pharma Company N V Borsa (NAMSW) Ultime notizie

American Century Companies Inc. Acquires Shares of 346,572 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

Teacher Retirement System of Texas Makes New $276,000 Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Leading Cardiovascular Drug Developer NewAmsterdam Sets Key Investor Presentation - Stock Titan

Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 By Investing.com - Investing.com Australia

Newamsterdam Pharma director James Topper buys $25,520 in shares By Investing.com - Investing.com Australia

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National Bank - Defense World

Newamsterdam pharma COO sells shares worth $376,000 By Investing.com - Investing.com Canada

Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 - Investing.com India

Newamsterdam pharma COO sells shares worth $376,000 - Investing.com India

Newamsterdam Pharma director James Topper buys $25,520 in shares - Investing.com

Newamsterdam Pharma COO Kling sells $2.36 million in stock By Investing.com - Investing.com Australia

Newamsterdam Pharma COO Kling sells $2.36 million in stock - Investing.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DE - Defense World

NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Consensus Price Target from Analysts - Defense World

Financial Metrics Exploration: Understanding NewAmsterdam Pharma Company NV (NAMS) Through Ratios - The Dwinnex

9,983 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Keybank National Association OH - Defense World

A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News

Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com Australia

Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com

New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com India

New Amsterdam Pharma chief accounting officer sells $3.06 million in shares By Investing.com - Investing.com South Africa

William Blair Has Negative Forecast for NAMS Q1 Earnings - Defense World

NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $52.00 - Defense World

(NAMS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution (NASDAQ:NAMS) - Seeking Alpha

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress - TipRanks

7 Analysts Have This To Say About NewAmsterdam Pharma - Benzinga

Scotiabank raises NewAmsterdam Pharma target to $52 - Investing.com India

Scotiabank raises NewAmsterdam Pharma target to $52 By Investing.com - Investing.com South Africa

Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence - TipRanks

NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises -February 26, 2025 at 08:27 am EST - Marketscreener.com

Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M - Marketscreener.com

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView

Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction - StockTitan

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - The Manila Times

NewAmsterdam Pharma Company N.V. (NAMS): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey

Newamsterdam Pharma Company N V Azioni (NAMSW) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a NAMSW